Aurobindo Pharma Ltd

About Aurobindo Pharma Ltd

Aurobindo Pharma Ltd. is a prominent Indian pharmaceutical company specializing in the manufacturing of active pharmaceutical ingredients (APIs), intermediates, and a diverse portfolio of finished dosages. With a strong global presence, it focuses on generics across various therapeutic areas, positioning itself as a major player in the worldwide generic pharmaceutical market.

Key Financial Ratios of Aurobindo Pharma Ltd

• P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Aurobindo Pharma Ltd's P/E ratio (TTM) is 19.77, compared to the industry median of 19.41 and large cap median of 32.56.

• P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Aurobindo Pharma Ltd's P/B ratio is 1.93, compared to the industry median of 1.98 and large cap median of 1.93.

• P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Aurobindo Pharma Ltd's P/S ratio is 2.13, compared to the industry median of 2.06 and large cap median of 2.13.

• PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Aurobindo Pharma Ltd's PEG ratio is 5.02.

• EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Aurobindo Pharma Ltd's EV/EBITDA ratio is 8.39.

• Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Aurobindo Pharma Ltd's ROE is 9.24%.

• Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Aurobindo Pharma Ltd's ROA is 11.80%.

• Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Aurobindo Pharma Ltd's ROCE is 13%.

• Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Aurobindo Pharma Ltd's operating margin is 20.41%.

• Net Margin: Net margin shows what percentage of revenue converts into final net profit. Aurobindo Pharma Ltd's net margin is 10.41%.

• Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Aurobindo Pharma Ltd's current ratio is 1.81.

• Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Aurobindo Pharma Ltd's debt-to-equity ratio is 0.03.

• Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Aurobindo Pharma Ltd's interest coverage ratio is 14.31.

• Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Aurobindo Pharma Ltd's DPS is ₹4.22.

• Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Aurobindo Pharma Ltd's EPS is 0.53.

(Source line: "Ratios as of 20 Feb 2026, based on last traded price of ₹1165. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")

Key Facts

• Founded: 1986

• Headquarters: Hyderabad, Telangana

• Core Offerings: APIs, Finished Dosages, Generics, Biosimilars, Specialty Products

• Stock Listing: NSE (AUROPHARMA), BSE (524804)

• Promoter: P.V. Ramprasad Reddy & K. Nityananda Reddy / Promoter Group

History of Aurobindo Pharma Ltd

Aurobindo Pharma was incorporated in 1986 and commenced operations in 1988 with a single manufacturing unit. It went public in 1992, listing on Indian stock exchanges. The company expanded significantly over the decades, establishing a strong presence in global markets, particularly the US and Europe, through a focus on generic formulations and APIs. Key milestones include strategic acquisitions to bolster its product portfolio and manufacturing capabilities, alongside venturing into high-value segments like biosimilars and injectables.

Business Segments and Revenue Mix

• Formulations: Focuses on developing, manufacturing, and marketing generic finished dosage forms across diverse therapeutic areas like anti-retrovirals, CNS, CVS, gastroenterology, anti-diabetics, and anti-infectives for various regulated and semi-regulated markets globally.

• Active Pharmaceutical Ingredients (APIs): Produces a wide range of APIs not only for captive consumption in its formulations business but also for sale to other pharmaceutical companies worldwide, ensuring backward integration and cost efficiency.

• Specialty & Biosimilars: Investing in and developing complex injectables, biosimilars, and other specialty products to move up the value chain and cater to niche high-growth segments.

• Research & Development: Operates extensive R&D facilities dedicated to developing new products, improving manufacturing processes, and ensuring regulatory compliance across its portfolio.

Key Personnel

N. Govindarajan, Managing Director & CEO. He holds extensive experience in the pharmaceutical industry, having previously served in leadership roles with over three decades of experience in operations, supply chain, and business management.

Subsidiaries and Associate Companies

• Aurobindo Pharma USA, Inc.

• Eugia Pharma Specialities Limited

• Aurobindo Pharma (Europe) Ltd.

• APL Healthcare Limited

Corporate Actions

No major recent corporate actions on record.

References

1. Annual Report [Latest Year] 2. Exchange Filings (NSE/BSE) 3. Financial Results Announcement